Dole, Employees Give to Restore and Rebuild Devastated Central America
1.6.2021 17:15:00 EEST | Business Wire | Press release
On November 3, 2020 Hurricane Eta made landfall in Central America as a powerful Category 4 storm. Just two weeks later Hurricane Iota, a Category 5 storm followed nearly the same path through the region, unleashing heavy rains, winds, massive flooding and severe landslides, causing widespread destruction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005255/en/
Replanting bananas in Honduras. Restoring fields and livelihoods destroyed by Hurricanes Eta and Iota in November 2020. (Photo: Business Wire)
Communities and towns in Honduras and Guatemala - many that support Dole farms and workers – were leveled in the wake. Though Dole was able to successfully evacuate its workers and families prior to the hurricanes’ arrivals, many others were not as fortunate and lost their lives or livelihoods, their possessions and their crops. In the aftermath, water was needed to drink, homes were in need of repair, and clothes, supplies and appliances in need of replacement.
As an organization closely connected to these communities through the banana industry, Dole swiftly moved to lend aid and resources. But not just the company as an entity stepped in, many Dole employees, partners, and public supporters —no matter how far physically from these communities — also contributed their own time and their own funds to help.
In these six months since the hurricanes’ devastation much has been accomplished.
- Dole employees, the company and the public together raised, collected and donated a quarter of a million dollars to purchase food baskets of essential food items -- red beans, rice, corn flour, vegetable oil and powdered milk, capable of feeding a family of five for a month. These food baskets were distributed to 10,000 families in-need in communities surrounding our operations and through relief organizations CEPUDO and the Cortés Chamber of Commerce with established distribution networks in other areas.
- The Red Cross of Honduras received donations of dozens of boxes of clothing and footwear contributed by Dole employees in North America and Dole’s Standard Fruit De Honduras. In addition to 500,000 Lempiras ($20,000US) to help those in need and provide support.
- Dole provided use of company machinery and heavy equipment to repair public services, bridges, roads, and highways.
- Dole allocated space on southbound vessels to humanitarian organizations importing and distributing disaster relief goods and equipment.
- With many banana production areas completely destroyed, Dole, as a major employer of choice in the region, has expedited efforts to restore banana plantations to full production. Farm land preparation takes time and is completely tailored to the conditions of each agricultural area, yet returning jobs and paychecks to the areas quickly is critical.
“I cannot sufficiently convey the heartbreaking destruction these communities endured,” said Nelson Montoya President of Dole Fresh Fruit North America. “However, this catastrophe did not defeat them. The compassion, resiliency and camaraderie of all those on our team in Honduras and Guatemala has been inspiring to me. We will continue to invest in getting everyone back on their feet.”
The investment reached a significant milestone in the rehabilitation process in Honduras, with the first planting of new banana fields at Mendez Farm, Barimasa Zone on May 4, followed closely with planting at Copote Farm in the Isletas Zone and most recently the Palo Verde farm in the Coyoles Zone.
As the company works to restore production volumes derived from these devastated areas in Honduras and Guatemala, Dole expects customers will begin receiving Dole premium fruit from these regions in January 2022.
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005255/en/
Contact information
William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
